Fanfare marks Novartis' move to new UK home
Big names from the government and life sciences, as well as top brass from Novartis (NOVN: VX), were in attendance as the Swiss pharma giant marked the official opening of its new UK headquarters.
Novartis has focused communications around the opening of the new site in White City, west London, on its launch of a new UK-centered clinical trial of the cardiovascular candidate inclisiran, which the company acquired in its $9.7 billion buy of The Medicines Company last year.
The company also confirmed on Tuesday that it would expand Novartis Biome to the UK. This program is a digital innovation lab that aims to empower and engender health tech companies and people to disrupt healthcare through the use of data and digital technologies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze